Myasthenia Gravis is a relatively rare an autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatigue. Myasthenia gravis (MG) with symptoms limited to eye muscles [ocular MG (OMG)] is a rare disease. Ocular Myasthenia Gravis. Toth L, Toth A, Dioszeghy P, Repassy G. Electronystagmographic analysis of optokinetic nystagmus for the evaluation of ocular symptoms in myasthenia gravis. Oropharyngeal muscle weakness, difficulty chewing tough, chewy or fibrous foods, swallowing, or talking, is the initial symptom in one-sixth of patients, and limb weakness in only 10%. Commonly, MG affects the ocular muscles first. The TNF-α-863 polymorph-ism might be linked with ocular myasthenia gravis asso- Ocular myasthenia gravis is a form of myasthenia gravis (MG) in which the muscles that move the eyes and con­trol the eyelids are easily fatigued and weakened. Myasthenia gravis (MG) is a common autoimmune disorder caused by the production of autoantibodies against nicotinic acetylcholine receptors at the neuromuscular junction [1, 2].The disruption of the neuromuscular pathway causes reduced stimulation of the muscles manifesting as fatigable muscle weakness, which may be generalized or focal, specifically involving ocular and bulbar … To date, only 7 patients with MG have been reported to have nocardiosis. Some experts consider video-assisted thoracoscopic thymectomy in purely ocular myasthenia gravis. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Toth L, Toth A, Dioszeghy P, Repassy G. Electronystagmographic analysis of optokinetic nystagmus for the evaluation of ocular symptoms in myasthenia gravis. Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. Ocular Myasthenia Dr Maruthi Prasad Upputuri. MG is a neuromuscular junction disease caused in 85% of the cases by acetylcholine receptor (AChR) antibodies. 8% of patients with myasthenia gravis [2]. In recent years, both an increase in incidence rate, particularly in the elderly, and a lower risk for secondary generalization may have contributed to the growing disease prevalence in Western countries. INTRODUCTION